NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

AI Briefing

• – NovaBridge and Visara announce positive results from Phase 2a VIS-101 study for wet AMD.
• – VIS-101 shows rapid, robust and durable treatment responses with potential best-in-class durability and favorable safety profile.
• – Topline results show VIS-101 is effective for treating wet AMD, a condition affecting over 20 million people globally.